HOUSE OF REPRESENTATIVES ~ 1032 THIRTY-FIRST LEGISLATURE, 2021 IN H.D. I STATE OF HAWAII a A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
1 SECTION 1. Section 329—14, Hawaii Revised Statutes, is
2 amended as follows:
3 1. By amending subsection (b) to read:
4 “(b) Any of the following opiates, including their
5 isomers, esters, ethers, salts, and salts of isomers, esters,
6 and ethers, unless specifically excepted, whenever the existence
7 of these isomers, esters, ethers, and salts is possible within
8 the specific chemical designation:
9 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
10 phenethyl) —4-piperidinyl] -N-phenylacetamide);
11 (2) Acetylmethadol;
12 (3) Allyiprodine;
13 (4) Aiphacetylmethadol (except levo-alphacetylmethadol,
14 levomethadyl acetate, or LAAM);
15 (5) Aiphameprodine;
16 (6) Aiphamethadol;
2021—2263 HB1032 HD1 HMSO Page2 H.B. NCD. ~g~1
1 (7) Aipha-methylfentanyl (N- [1- (alpha-methyl-beta-
2 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
3 2-phenylethyl)-4-(N-propanilido) piperidine);
4 (8) Alpha-methylthiofentanyl (N—[1-methyl-2-(2-
5 thienyl) ethyl—4-piperidinyl] -N-phenylpropanamide);
6 (9) Benzethidine;
7 (10) Betacetylmethadol;
8 (11) Beta-hydroxyfentanyl (N- [1- (2-hydroxy-2-phenethyl) -4-
9 piperidinyl] -N-phenylpropanamide);
10 (12) Beta-hydroxy-3-methylfentariyl (N-[1-(2-hydroxy-2-
11 phenethyl) -3-methyl-4-piperidinyl] -N-
12 phenyipropanamide);
13 (13) Betameprodine;
14 (14) Betamethadol;
15 (15) Betaprodine;
16 (16) Clonitazene;
17 (17) Dextromoramide;
18 (18) Diampromide;
19 (19) Diethyithiambutene;
20 (20) Difenoxin;
21 (21) Dimenoxadol;
2021—2263 HB1032 HD1 HMSO 2 H.B. NO. ~
1 (22) Dimepheptanol;
2 (23) Dimethyithiambutene;
3 (24) Dioxaphetyl butyrate;
4 (25) Dipipanone;
5 (26) Ethylmethyithiambutene;
6 (27) Etonitazene;
7 (28) Etoxeridine;
8 (29) Furethidine;
9 (30) Hydroxypethidine;
10 (31) Ketobemidone;
11 (32) Levomoramide;
12 (33) Levophenacylmorphan;
13 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
14 piperidyl] -N-phenylpropanamide);
15 (35) 3-methyithiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
16 4-piperidinyl] -N-phenylpropanamide);
17 (36) Morpheridine;
18 (37) MPPP (1-methyl-4-phenyl-4--propionoxypiperidine);
19 (38) Noracymethadol;
20 (39) Norlevorphanol;
21 (40) Normethadone;
2021—2263 HB1032 HD1 HMSO 3 H.B. NO. ~
1 (41) Norpipanone;
2 (42) Para—fluorofentanyl (N—(4—fluorophenyl)-N—[1-(2-
3 phenethyl) —4-piperidinyl] propanamide;
4 (43) PEPAP (1-(—2-phenethyl)-4-phenyl-4-acetoxypiperidine;
5 (44) Phenadoxone;
6 (45) Phenampromide;
7 (46) Phenomorphan;
8 (47) Phenoperidine;
9 (48) Piritramide;
10 (49) Proheptazine;
11 (50) Properidine;
12 (51) Propiram;
13 (52) Racemoramide;
14 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
15 piperidinyl] -propanamide);
16 (54) Tilidine;
17 (55) Trimeperidine;
18 (56) N- (1-benzyl-4-piperidyl] -N-phenylpropanamide
19 (benzylfentanyl), its optical isomers, salts, and
20 salts of isomers;
2021—2263 HB1032 HD1 HMSO 4 Page5 H.B. NC). ~
1 (57) N—[l—(2—thienyl)methyl—4—piperidyl]—N—
2 phenyipropanamide (thenylfentanyl), its optical
3 isomers, salts, and salts of isomers;
4 (58) N-(l-phenethylpiperidin-4-yl)-N-phenylacetamide,
5 (acetyl fentanyl), its optical, positional, and
6 geometric isomers, salts, and salts of isomers;
7 (59) AH—792l (3,4—dichloro—N—[(1—dimethylamino)
8 cyclohexylmethyl]benzamide), its isomers, esters,
9 ethers, salts, and salts of isomers, esters, and
10 ethers;
11 (60) N-(l-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
12 isomers, esters, ethers, salts, and salts of isomers,
13 esters, and ethers (Other names: Butyryl fentanyl);
14 (61) N—[l—[2—hydroxy—2-(thiophen—2-yl)ethyl]piperidin—4-
15 yl]—N—phenylpropionamide, its isomers, esters, ethers,
16 salts, and salts of isomers, esters, and ethers (Other
17 names: beta-hydroxythiofentanyl);
18 (62) N—(l—phenethylpiperidin-4—yl)—N-phenvlfuran—2-
19 carboxamide, its isomers, esters, ethers, salts, and
20 salts of isomers, esters, and ethers (Other names:
21 Furanyl fentanyl);
2021—2263 HB1O32 HD1 HMSO 5 H.B. NCD. ~
1 (63) 3,4-dichloro—N—[2—(dimethylamino)cvclohexyl]-N-
2 methvlbenzamide, its isomers, esters, ethers, salts,
3 and salts of isomers, esters, and ethers (Other names:
4 U—47700)
5 (64) 4—fluoroisobutyryl fentanyl or para-fluoroisobutyryl
6 [fcnranyl] fentanyl [N-(4-fluorophenyl)-N-(1-
7 phenethylpiperidin-4-yl) isobutyramide];
8 (65) Acryl fentanyl or acryloylfentanyl [N—(1—
9 phenethylpiperidin-4-yl) -N-phenylacrylamide]; La-~]
10 (66) Ocfentanil [[N (2 fluorophcnyl)—2-mcthoxy-N—(l—
11 phcncthylpiprtidin 4 yl)acctamidc] .1 [N—(2-
12 fluorophenyl) —2-methoxy-N- (l-phenethylpiperidin-4-
13 yl)acetamide];
14 (67) Cyclopropyl fentanyl (N-(l-phenethylpiperidin-4-yl)-N-
15 phenylcyclopropanecarboxamide;
16 (68) Methoxyacetyl fentanyl (2-methoxy-N-(1-
17 phenethylpiperidin-4-yl) —N-phenylacetamide);
18 (69) Ortho—fluorofentanyl (N—(2-fluorophenyl)—N-(1-
19 phenethylpiperidin-4-yl)propionamide) (Other name: 2-
20 fluorofentanyl); and
2021—2263 HB1032 HD1 HMSO 6 H.B. NED. ~i
1 (70) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(l-
2 phenethylpiperidin-4-yl) butyramide) •uI
3 2. By amending subsection Ce) to read:
4 “Ce) Depressants. Unless specifically excepted, the
5 schedule shall include any material, compound, mixture, or
6 preparation which contains any quantity of the substance:
7 (1) Mecloqualone; [e~]
8 (2) Methaqualone[--];
9 (3) Etizolam (including its optical, positional, and
10 geometric isomers, salts, and salts of isomers, where
11 possible) ; or
12 (4) Flualprazolam (including its optical, positional, and
13 geometric isomers, salts, and salts of isomers, where
14 possible) .“
15 3. By amending subsection (g) to read:
16 “(g) Any of the following cannabinoids, their salts,
17 isomers, and salts of isomers, unless specifically excepted,
18 whenever the existence of these salts, isomers, and salts of
19 isomers is possible within the specific chemical designation:
20 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
21 naturally contained in a plant of the genus Cannabis
2021—2263 HB1032 HD1 HMSO 7 H.B. NO. ~
1 (cannabis plant), as well as synthetic equivalents of
2 the substances contained in the plant, or in the
3 resinous extractives of Cannabis, sp. or synthetic
4 substances, derivatives, and their isomers with
5 similar chemical structure and pharmacological
6 activity to those substances contained in the plant,
7 such as the following: Delta 1 cis or trans
8 tetrahydrocannabinol, and their optical isomers; Delta
9 6 cis or trans tetrahydrocannabinol, and their optical
10 isomers; and Delta 3,4 cis or trans
11 tetrahydrocannabinol, and its optical isomers (since
12 nomenclature of these substances is not
13 internationally standardized, compounds of these
14 structures, regardless of numerical designation of
15 atomic positions, are covered) ;
16 (2) Naphthoylindoles; meaning any compound containing a 3-
17 (1—naphthoyl)indole structure with substitution at the
18 nitrogen atom of the indole ring by a alkyl,
19 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
21 morpholinyl)ethyl group, whether or not further
2021—2263 HB1032 HD1 HMSO 8 H.B. NcD. ~
1 substituted in the indole ring to any extent and
2 whether or not substituted in the naphthyl ring to any
3 extent;
4 (3) Naphthylmethylindoles; meaning any compound containing
5 a 1H-indol-3-yl-(l-naphthyl) methane structure with
6 substitution at the nitrogen atom of the indole ring
7 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, l-(N-methyl-2-piperidinyl) methyl or
9 2-(4-morpholinyl) ethyl group whether or not further
10 substituted in the indole ring to any extent and
11 whether or not substituted in the naphthyl ring to any
12 extent;
13 (4) Naphthoylpyrroles; meaning any compound containing a
14 3-(l-naphthoyl)pyrrole structure with substitution at
15 the nitrogen atom of the pyrrole ring by a alkyl,
16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
17 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
18 ethyl group whether or not further substituted in the
19 pyrrole ring to any extent, whether or not substituted
20 in the naphthyl ring to any extent;
2021—2263 HB1032 HD1 HMSO 9 H.B. NCD. ~
1 (5) Naphthylmethylindenes; meaning any compound containing
2 a naphthylideneindene structure with substitution at
3 the 3-position of the indene ring by a alkyl,
4 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
5 l—(N—methyl—2—piperidinyl) methyl or 2—(4—morpholinyl)
6 ethyl group whether or not further substituted in the
7 indene ring to any extent, whether or not substituted
8 in the naphthyl ring to any extent;
9 (6) Phenylacetylindoles; meaning any compound containing a
10 3—phenylacetylindole structure with substitution at
11 the nitrogen atom of the indole ring by a alkyl,
12 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13 l—(N—methyl—2—piperidinyl) methyl or 2—(4-morpholinyl)
14 ethyl group whether or not further substituted in the
15 indole ring to any extent, whether or not substituted
16 in the phenyl ring to any extent;
17 (7) Cyclohexyiphenols; meaning any compound containing a
18 2-(3-hydroxycyclohexyl) phenol structure with
19 substitution at the 5-position of the phenolic ring by
20 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21 cycloalkylethyl, l-(N-methyl-2-piperidinyl) methyl or
2021—2263 HB1032 HD1 HMSO H.B. NcD. ~
1 2-(4-morpholinyl) ethyl group whether or not
2 substituted in the cyciohexyl ring to any extent;
3 (8) Benzoylindoles; meaning any compound containing a 3-
4 (benzoyl) indole structure with substitution at the
5 nitrogen atom of the indole ring by a alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 l—(N—methyl—2—piperidinyl) methyl, or 2-(4-
8 morpholinyl) ethyl group whether or not further
9 substituted in the indole ring to any extent and
10 whether or not substituted in the phenyl ring to any
11 extent;
12 (9) [2, 3—Dihydro—5-methyl-3— (4-morpholinylmethyl)
13 pyrrolo[1,2,3—de]—1, 4—benzoxazin—6-yl]—1—
14 naphthalenylmethanone (another trade name is WIN
15 55,212—2);
16 (10) (6a,lOa)-9—(hydroxymethyl)-6, 6—dimethyl—3—(2-
17 methyloctan-2—yl) —6a, 7,10, lOa
18 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
19 HU—210/HU—211)
20 (11) Tetramethylcyclopropanoylindoles; meaning any compound
21 containing a 3-tetramethylcyclopropanoylindole
2021—2263 HB1032 HOl HMSO 11 Page 12 H.B. ~
1 structure with substitution at the nitrogen atom of
2 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
3 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
4 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
5 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
6 morpholinyl)methyl, or tetrahydropyranylmethyl group,
7 whether or not further substituted in the indole ring
8 to any extent and whether or not substituted in the
9 tetramethylcyclopropyl ring to any extent;
10 (12) N-(1-adamantyl)-l-pentyl-1H-indazole-3-carboxamide,
11 its optical, positional, and geometric isomers, salts,
12 and salts of isomers (Other names: APINACA, AK348);
13 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
14 optical, positional, and geometric isomers, salts, and
15 salts of isomers (Other names: P3—22; QUPIC);
16 (14) Quinolin—8—yl 1—(5fluoropentyl)—1H—indole—3—
17 carboxylate, its optical, positional, and geometric
18 isomers, salts, and salts of isomers (Other names: 5-
19 fluoro-PB—22; 5F—P3—22);
20 (15) N- (1—amino—3—methyl—1—oxobutan—2—yl) -1-- (4-
21 fluorobenzyl) —1H—indazole—3-carboxamide, its optical,
2021—2263 HB1032 HD1 HMSO 12 H.B. ND. ~
1 positional, and geometric isomers, salts, and salts of
2 isomers (Other names: AB-FUBINACA);
3 (16) N—(l—amino—3,3-dimethyl—1—oxobutan—2-yl)—1—pentyl—1H-
4 indazole-3-carboxamide, its optical, positional, and
5 geometric isomers, salts, and salts of isomers (Other
6 names: ADB-PINACA);
7 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
8 (cyclohexylmethyl) -1H-indazole-3-carboxamide, its
9 optical, positional, and geometric isomers, salts, and
10 salts of isomers (Other names: AB-CHMINACA);
11 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
12 indazole—3—carboxamide, and geometric isomers, salts,
13 and salts of isomers (Other names: AB-PINACA);
14 (19) [1-(5-fluoropentyl)-1H-indazol-3--yl] (naphthalen-1-
15 yl)methanone, and geometric isomers, salts, and salts
16 of isomers (Other names: THJ—2201);
17 (20) Methyl [(1 (4 fluorobcnzyl) 1 H—iridazolc 3-carbonyl)
18 L valinatc,] (1— (4—fluorobenzyl) —1H-indazole-3—
19 carbonyl)-L-valinate, and geometric isomers, salts,
20 and salts of isomers (Other names: FUB-AMB[-)--t], Methyl
2021—2263 HB1032 HD1 HMSO 13 H.B. ~jc~ ~
1 2- (1- (4—fluorobenzyl) -1H-indazole-3-carboxamido) -3-
2 methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);
3 (21) (S)—methyl 2—(1—(5-fluoropentyl)—1H—indazole—3—
4 carboxamido)-3—methylbutanoate, and geometric isomers,
5 salts, and salts of isomers (Other names: 5-fluoro-
6 AMB, 5-fluoro-AMP);
7 (22) N—((3s,5s,7s)—adamantan—1—yl)—l—(5—fluoropentyl)—1H-
8 indazole—3—carboxamide, and geometric isomers, salts,
9 and salts of isomers (Other names: AKB48 N-(5-
10 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
11 analog, 5F-APINACA);
12 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
13 geometric isomers, salts, and salts of isomers (Other
14 names: STS—135, 5F-APICA; 5—fluoro—APICA);
15 (24) Naphthalen—1—yl l—(5-fluoropentyl)—1H—indole-3—
16 carboxylate, and geometric isomers, salts, and salts
17 of isomers (Other names: NM22O1);
18 (25) N—(1—amino—3,3—dimethyl—1—oxobutan—2-yl)--1—
19 (cyclohexylmethyl) -1H-indazole-3-carboxamide, and
20 geometric isomers, salts, and salts of isomers (Other
21 names: MAB-CHMINACA and ADB-CHMINACA);
2021—2263 HB1032 HD1 HMSO 14 H.B. N~J. ~
1 (26) Methyl 2-[1-(5—fluoropentyl)—1H—indazole—3-
2 carboxamido] -3, 3—dimethylbutanoate (Other names: 5F-
3 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
4 positional, and geometric isomers, salts, and salts of
5 isomers; and
6 (27) l-(4-cyanobutyl)—N-(2-phenylpropan-2-yl)indazole-3-
7 carboxamide (CUMYL-4CN-BINACA), its optical,
8 positional, and geometric isomers, salts, and salts of
9 isomers; also known as SGT—78, 4-CN-CUMYL-BINACA;
10 CUMYL-CE-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL
11 BUTINACA.”
12 SECTION 2. Section 329—16, Hawaii Revised Statutes, is
13 amended by amending subsection (f) to read as follows:
14 “(f) Immediate precursor. Unless listed in another
15 schedule, any material, compound, mixture, or preparation which
16 contains any quantity of the following substances:
17 (1) Immediate precursor to amphetamine and
18 methamphetamine:
19 (A) Phenylacetone, phenyl—2—propanone(P2P), benzyl
20 methyl ketone, methyl benzyl ketone;
21 (2) Immediate precursors to phencyclidine (POP)
2021—2263 HB1032 HD1 HMSO 15 H.B. NC). ~
1 (A) 1-phenylcyclohexylamirie; [~-~] or
2 (B) 1—piperidinocyclohexanecarbonitrile (PCC); or
3 (3) Immediate precursor to Fentanyl:
4 (A) 4-anilino-N-phenethyl-4-piperidine (ANPP) H-]; or
5 (B) N-phenyl-N- (piperidin-4-yl) propionamide
6 (norfentanyl) .“
7 SECTION 3. Section 329-20, Hawaii Revised Statutes, is
8 amended as follows:
9 1. By amending subsection (b) to read:
10 “(b) Depressants. Any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances, including its salts, isomers, esters, ethers, and
13 salts of isomers, whenever the existence of these isomers,
14 esters, ethers, and salts is possible within the specific
15 chemical designation, that has a degree of danger or probable
16 danger associated with a depressant effect on the central
17 nervous system:
18 (1) Alprazolam;
19 (2) Barbital;
20 (3) Bromazepam;
21 (4) Butorphanol;
2021—2263 HB1032 HD1 RMSO 16 H.B. NC). ~
1 (5) Camazepam;
2 (6) Carisoprodol;
3 (7) Chioral betairie;
4 (8) Chioral hydrate;
5 (9) Chiordiazepoxide;
6 (10) Clobazam;
7 (11) Clonazepam;
8 (12) Clorazepate;
9 (13) Clotiazepam;
10 (14) Cloxazolam;
11 (15) Delorazepam;
12 (16) Dichioraiphenazone (Midrin);
13 (17) Diazepam;
14 (18) Estazolam;
15 (19) Ethchlorvynol;
16 (20) Ethinamate;
17 (21) Ethyl loflazepate;
18 (22) Fludiazepam;
19 (23) F’lunitrazepam;
20 (24) Flurazepam;
21 (25) Fospropofol (Lusedra);
2021—2263 HB1032 HD1 HMSO 17 HB. NCD. ~g~1
1 (26) Halazepam;
2 (27) Haloxazolam;
3 (28) Ketazolam;
4 (29) Loprazolam;
5 (30) Lorazepam;
6 (31) Lormetazepam;
7 (32) Mebutamate;
8 (33) Medazepam;
9 (34) Meprobamate;
10 (35) Methohexital;
11 (36) Methyiphenobarbital (mephorbarbital);
12 (37) Midazolam;
13 (38) Nimetazepam;
14 (39) Nitrazepam;
15 (40) Nordiazepam;
16 (41) Oxazepam;
17 (42) Oxazolam;
18 (43) Paraldehyde;
19 (44) Petrichioral;
20 (45) Phenobarbital;
21 (46) Pinazepam;
2021—2263 HB1032 HD1 HMSO 18 H.B. NC). ~
1 (47) Prazepam;
2 (48) Quazepam;
3 (49) Suvorexant;
4 (50) Temazepam;
5 (51) Tetrazepam;
6 (52) Triazolam;
7 (53) Zaleplon;
8 (54) Zolpidem; La~]
9 (55) Zopiclone (Lunesta) H-]; and
10 (56) Brexanolone.”
11 2. By amending subsection (d) to read:
12 “(d) Stimulants. Unless listed in another schedule, any
13 material, compound, mixture, or preparation which contains any
14 quantity of the following substances having a stimulant effect
15 on the central nervous system, including its salts, isomers, and
16 salts of such isomers whenever the existence of such salts,
17 isomers, and salts of isomers is possible within the specific
18 chemical designation:
19 (1) Cathine ((+)-norpseudoephedrine);
20 (2) Diethyipropion;
21 (3) Fencamfamin;
2021—2263 H31032 HD1 HMSO 19 H.B. NC). ~
1 (4) Fenproporex;
2 (5) Mazindol;
3 (6) Mefenorex;
4 (7) Modafinil;
5 (8) Phentermine;
6 (9) Pemoline (including organometallic complexes and
7 chelates thereof);
8 (10) Pipradrol;
9 (11) Sibutramine;
10 (12) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine);
11 [~]
12 (13) Lorcaserin[--]; and
13 (14) Soiriamfetol.”
14 SECTION 4. Section 329—22, Hawaii Revised Statutes, is
15 amended to read as follows:
16 “~329-22 Schedule V. (a) The controlled substances
17 listed in this section are included in schedule V.
18 (b) Narcotic drugs containing nonnarcotic active medicinal
19 ingredients. Any compound, mixture, or preparation containing
20 limited quantities of any of the following narcotic drugs, which
21 also contains one or more nonnarcotic active medicinal
2021—2263 HB1032 HD1 HMSO 20 H.B. NO. ~
1 ingredients in sufficient proportion to confer upon the
2 compound, mixture, or preparation, valuable medicinal qualities
3 other than those possessed by the narcotic drug alone:
4 (1) Not more than 200 milligrams of codeine, or any of its
5 salts, per 100 milliliters or per 100 grams;
6 (2) Not more than 100 milligrams of dihydrocodeine, or any
7 of its salts, per 100 milliliters or per 100 grams;
8 (3) Not more than 100 milligrams of ethylmorphine, or any
9 of its salts, per 100 milliliters or per 100 grams;
10 (4) Not more than 2.5 milligrams of diphenoxylate and not
11 less than 25 micrograms of atropine sulfate per dosage
12 unit;
13 (5) Not more than 100 milligrams of opium per 100
14 milliliters or per 100 grams; and
15 (6) Not more than 0.5 milligram of difenoxin and not less
16 than 25 micrograms of atropine sulfate per dosage
17 unit.
18 (c) Stimulants. Unless specifically exempted or excluded
19 or unless listed in another schedule, any material, compound,
20 mixture, or preparation that contains any quantity of the
21 following substances having a stimulant effect on the central
2021—2263 HB1032 HD1 HMSO 21 H.B. NcJ. ~
1 nervous system, including its salts, isomers, and salts of
2 isomers.
3 (d) Depressants. Unless specifically exempted or excluded
4 or unless listed in another schedule, any material, compound,
5 mixture, or preparation that contains any quantity of the
6 following substances having a depressant effect on the central
7 nervous system, including its salts, isomers, and salts of
8 isomers:
9 (1) Lacosamide E (R) -2-acetoamido-N-benzyl-3-methoxy-
10 propionamide], (Vimpat);
11 (2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
12 acid]; and
13 (3) Brivaracetam ((2S)—2[(4R)—2—oxo—4—propylpyrrolidin-1-
14 yl]butanamide) (Other names: BRV; UCB-34714; Briviact)
15 and its salts.
16 [(c) T~pprovcd cannabidiol drugs ~
17 finishcd dosagc formulation that has bccn approvcd by thc Unitcd
18 Statcs Food ~d Dri~ Administrati~ that contai~ ~~~bidiol
19 (2-[1R—~—mcthy1-~°—(l mcthylcthcnyl)-’~1-1-~11~-•y ‘— ~ ~ ~ ‘.— p L A I A.. a A.. J ._.I
20 ~tyl 1, 3 b~~~cdiol’. cic~r- I I rOTE) 000flflhi nnH nn mnrc~ tHnn
21 0 . 1 pcrccnt (w/w~ zidual tctrahydrocannabinols.]”
2021—2263 HB1032 HD1 HMSO 22 H.B. NO. ~
1 SECTION 5. Statutory material to be repealed is bracketed
2 and stricken. New statutory material is underscored.
3 SECTION 6. This Act shall take effect upon its approval.
2021—2263 HB1032 HD1 HMSO 23 H..B. NED. ~
Report Title: Uniform Controlled Substances Act
Description: Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329—11, Hawaii Revised Statutes. (HD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
2021—2263 HB1O32 HD1 HMSO